title: Biotherapy in the Adjuvant Treatment of Colorectal Cancer.
abstract: The use of adjuvant chemotherapy has improved survival in early-stage colon cancer. Ongoing adjuvant clinical trials are evaluating the addition of targeted therapies to standard chemotherapy regimen. Preliminary results with bevacizumab were disappointing. Also, cetuximab added to chemotherapy does not seem to be better than chemotherapy alone, even in selected wild-type KRAS populations. A better understanding of mechanisms of action of drugs, tumor biology, and predictive biomarkers are needed to design future adjuvant trials.
authors.affiliation: Department of Medical Oncology, National Institute of Oncology, Rabat, Morocco.
authors.forename: El Mehdi
authors.initials: EM
authors.lastname: Tazi
authors.affiliation: Department of Medical Oncology, National Institute of Oncology, Rabat, Morocco.
authors.forename: Ismail
authors.initials: I
authors.lastname: Essadi
authors.affiliation: Department of Medical Oncology, National Institute of Oncology, Rabat, Morocco.
authors.forename: Saber
authors.initials: S
authors.lastname: Boutayeb
authors.affiliation: Department of Medical Oncology, National Institute of Oncology, Rabat, Morocco.
authors.forename: Hind
authors.initials: H
authors.lastname: M'rabti
authors.affiliation: Department of Medical Oncology, National Institute of Oncology, Rabat, Morocco.
authors.forename: Hassan
authors.initials: H
authors.lastname: Errihani
keywords: Bevacizumab; Cetuximab; FOLFIRI; FOLFOX; K-ras